Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lithium cation. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lithium cation. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lithium cation. |
| Hydrocodone | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Lithium cation can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lithium cation. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lithium cation. |
| Orphenadrine | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lithium cation. |
| Pramipexole | Lithium cation may increase the sedative activities of Pramipexole. |
| Ropinirole | Lithium cation may increase the sedative activities of Ropinirole. |
| Rotigotine | Lithium cation may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Lithium cation. |
| Sodium oxybate | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lithium cation. |
| Thalidomide | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Lithium cation may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Lithium cation is combined with Methylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lithium cation. |
| Metyrosine | Lithium cation may increase the sedative activities of Metyrosine. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Lithium cation. |
| Sulpiride | Lithium cation may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Lithium cation. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Lithium cation. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Lithium cation. |
| Mequitazine | Lithium cation may increase the arrhythmogenic activities of Mequitazine. |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Lithium cation is combined with Tetrabenazine. |
| Deutetrabenazine | The risk or severity of adverse effects can be increased when Lithium cation is combined with Deutetrabenazine. |
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Lithium cation is combined with Foscarnet. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Lithium cation. |
| Tenofovir disoproxil | Lithium cation may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | Lithium cation may increase the nephrotoxic activities of Tenofovir alafenamide. |
| Tenofovir | Lithium cation may increase the nephrotoxic activities of Tenofovir. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Lithium cation. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Lithium cation is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Lithium cation is combined with Phenindione. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Lithium cation is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Lithium cation is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Lithium cation is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Lithium cation is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Lithium cation is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Lithium cation is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Lithium cation is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Lithium cation is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Lithium cation is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Lithium cation is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Lithium cation is combined with (S)-Warfarin. |
| Tedizolid phosphate | The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Lithium cation. |
| Mirtazapine | Lithium cation may increase the serotonergic activities of Mirtazapine. |
| Ethanol | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Lithium cation may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lithium cation. |
| Zimelidine | The risk or severity of adverse effects can be increased when Lithium cation is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Lithium cation is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Lithium cation is combined with Seproxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Lithium cation is combined with Sertraline. |
| Indalpine | The risk or severity of adverse effects can be increased when Lithium cation is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Lithium cation is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Lithium cation is combined with Alaproclate. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Lithium cation is combined with Fluvoxamine. |
| Duloxetine | The risk or severity of adverse effects can be increased when Lithium cation is combined with Duloxetine. |
| Sibutramine | The risk or severity of adverse effects can be increased when Lithium cation is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Lithium cation is combined with Nefazodone. |
| Milnacipran | The risk or severity of adverse effects can be increased when Lithium cation is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Lithium cation. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Lithium cation is combined with Levomilnacipran. |
| Paroxetine | The risk or severity of adverse effects can be increased when Lithium cation is combined with Paroxetine. |
| Methylene blue | Lithium cation may increase the serotonergic activities of Methylene blue. |
| Cyclosporine | The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Lithium cation. |
| Cefotiam | The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Lithium cation. |
| Cefmenoxime | The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Lithium cation. |
| Cefmetazole | The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Lithium cation. |
| Pamidronic acid | The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Lithium cation. |
| Cidofovir | The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Lithium cation. |
| Triamterene | The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Lithium cation. |
| Cefpiramide | The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Lithium cation. |
| Ceftazidime | The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Lithium cation. |
| Loracarbef | The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Lithium cation. |
| Cefalotin | The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Lithium cation. |
| Cefotaxime | The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Lithium cation. |
| Methotrexate | The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Lithium cation. |
| Cephalexin | The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Lithium cation. |
| Valaciclovir | The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Lithium cation. |
| Bacitracin | The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Lithium cation. |
| Amphotericin B | The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Lithium cation. |
| Cephaloglycin | The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Lithium cation. |
| Adefovir dipivoxil | The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Lithium cation. |
| Acyclovir | The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Lithium cation. |
| Cefaclor | The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Lithium cation. |
| Tacrolimus | The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Lithium cation. |
| Ceforanide | The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Lithium cation. |
| Carboplatin | The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Lithium cation. |
| Cefditoren | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Lithium cation. |
| Atazanavir | The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Lithium cation. |
| Colistimethate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Lithium cation. |